

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/049876-2025>

Contract

Storage and Distribution of Cellular Therapy Products Autologous Service Provision

Norfolk and Norwich University Hospitals NHS Foundation Trust

F03: Contract award notice

Notice identifier: 2025/S 000-049876

Procurement identifier (OCID): ocids-h6vhtk-058aa1

Published 19 August 2025, 2:56pm

Section I: Contracting authority

I.1) Name and addresses

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane

Norwich

NR4 7UY

Contact

James Anderson

Email

james.anderson@nnuh.nhs.uk

Country

United Kingdom

Region code

UKH15 - Norwich and East Norfolk

Internet address(es)

Main address

<https://www.nnuh.nhs.uk>

Buyer's address

<https://www.nnuh.nhs.uk>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Storage and Distribution of Cellular Therapy Products Autologous Service Provision

Reference number

C378402

II.1.2) Main CPV code

- 85111810 - Blood analysis services

II.1.3) Type of contract

Services

II.1.4) Short description

Contract for storage and distribution of stem cells

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £200,000

II.2) Description

II.2.3) Place of performance

NUTS codes

- UKH1 - East Anglia

II.2.4) Description of the procurement

Services to include processing and storage of stem cells

This notice is an intention to award a contract under the PSR Most Suitable Provider process.

The approximate lifetime value of this contract will be £200,000.

This is an existing service

This will be a new provider

The services will be provided between 1st February 2026 and 31st March 2027.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by [Add date]. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

19 August 2025

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

NHS BLOOD AND TRANSPLANT (NHSBT)

500 North Bristol Park, Filton, Bristol

Bristol

BS34 7QH

Telephone

+44 7764280366

Country

United Kingdom

NUTS code

- UK - United Kingdom

National registration number

972779

Internet address

<http://www.cromalocksmiths.com>

The contractor is an SME

Yes

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £200,000

Lowest offer: £200,000 / Highest offer: £200,000 taken into consideration

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by [Add date]. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Communication can be directed to james.anderson@nnuh.nhs.uk

The award decision makers include the Business Manager, Contracts Manager, Procurement Manager, and representation from the Operational teams. There are no declared conflicts or potential conflicts of interest of individuals making the decision.

1) Quality and Innovation

NHS Blood and Transplant (NHSBT) has a well-established reputation for delivering services that meet international standards, including support for JACIE-accredited centres. Their expertise in specialist techniques such as CD34+ cell selection, red blood cell depletion, and viability testing contributes directly to improving clinical safety and precision. The service is underpinned by strong quality assurance processes and full traceability, ensuring that patients benefit from safe, reliable and compliant stem cell processing.

2) Value

NHSBT provides a competitively priced service which includes cryopreservation, storage, and a comprehensive suite of testing. Their pricing model offers transparency and good value for money, with bundled services helping to reduce administrative burden and streamline processes. The inclusion of additional services such as donor testing and pre/post-processing enumeration adds further value without extra cost, supporting both operational efficiency and affordability.

3) Integration, Collaboration and Service Sustainability

The service is well aligned with the needs of both NNUH and James Paget University Hospital, with NHSBT already working in partnership with multiple NHS Trusts. Their ability to integrate into existing care pathways and respond flexibly to clinical demands will make them a reliable supplier. The long-term viability of the service will be supported by robust infrastructure, shared systems, and a commitment to continuity of care across the Norfolk and Waveney System.

4) Improving Access, Reducing Health Inequalities and Facilitating Choice

Faster processing and testing times mean patients can access treatment more quickly, which is particularly important in time-sensitive transplant cases. NHSBT's national infrastructure supports equitable access for patients at the NNUH, helping to reduce health inequalities across the Norfolk and Waveney area - in particular for patients from more remote or underserved areas. This in turn increases patient choice and ensures fairer access to specialist treatment.

5) Social Value

NHSBT delivers strong social value through investment in training, development, and local workforce support. They are actively involved in delivering against NHS sustainability goals, including reducing waste and supporting lower-carbon logistics. Their ethical sourcing policies and commitment to workforce wellbeing also contribute positively to the wider objectives of the NNUH and the NHS as a whole.

VI.4) Procedures for review

VI.4.1) Review body

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Email

england.commercialqueries@nhs.net

Country

United Kingdom

Internet address

<https://www.england.nhs.uk/>

VI.4.2) Body responsible for mediation procedures

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Email

england.commercialqueries@nhs.net

Country

United Kingdom

Internet address

<https://www.england.nhs.uk/>